Xigduo Xr Patent Expiration

XIGDUO XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 2 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(6 years from now)



Xigduo Xr is a drug owned by Astrazeneca Ab. It is used for managing type 2 diabetes mellitus when glycemic control is not achievable with other medications. Xigduo Xr uses Dapagliflozin; Metformin Hydrochloride as an active ingredient. Xigduo Xr was launched by Astrazeneca Ab in 2017. It is is available in tablet, extended release form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 12, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 28 July, 2017

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage

XIGDUO XR family patents

Family Patents